Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
VitalHub Corp. Benefitting From Recent UK Government Initiatives
-
Churchill Resources to Present at the Emerging Growth Conference January 11, 2024
-
BlackDice and Orion Telekom Collaboration Marks a Significant Leap Forward in Cybersecurity
-
Surgery Partners, Inc. Reaffirms 2023 Full Year Guidance and Provides 2024 Initial Adjusted EBITDA Outlook
-
Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients
-
Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA
-
Morgan Stanley Initiates Research Coverage on Mondee
-
Abeona Therapeutics Announces $50 Million Credit Facility
-
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
-
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-
-
Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
-
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders
-
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
-
Aurora Spine Announces Attendance at J.P. Morgan Healthcare Conference
-
Enovix and Group14 Announce Collaboration to Develop Best-in-Class Silicon Batteries
-
Tecan to present at upcoming Investor Conferences
-
Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme
-
Fyda Announces Launch of Decentralized Trade Automation Platform
-
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
-
WEMIX PLAY starts 2024 on strong footing by onboarding its first F2P Mobile Dance&Play Rhythm Game: Ritmi
-
WEMIX PLAY starts 2024 on strong footing by onboarding its first F2P Mobile Dance&Play Rhythm Game: Ritmi
-
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
-
Solid Biosciences Announces $109 Million Private Placement
-
Major shareholder announcement
-
First Watch Restaurant Group, Inc. Reports Preliminary Operational Metrics for the Fourth Quarter and Fiscal Year 2023
-
BurgerFi Provides Fiscal Year 2023 Business Update
-
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates
-
The Future of NFTs is Here: Universal Page launches Gasless NFT 2.0 Marketplace
-
Fortrea Previews J.P. Morgan Healthcare Conference Updates
-
Relay Therapeutics Announces $30 Million Private Placement Financing
-
First Watch to Acquire 21 Franchise Restaurants in North Carolina
-
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
-
NioBay Intercepts Niobium in the Extension of Its Main Zone at Crevier
-
Emerita Resources 2023 Year-In-Review: Maiden NI 43-101 Compliant Resource Estimate Delivered, Exploitation License Application Submitted, Drilling Ongoing
-
CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook
-
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
-
Atlas Technical Consultants Announces Leadership Change, Names Jacqueline Hinman Chief Executive Officer
-
Abercrombie & Fitch Co. Increases Fourth Quarter Sales and Operating Margin Outlook Based on Better-Than-Expected Holiday Sales
-
Potbelly Corporation Reports Preliminary Results for Fourth Fiscal Quarter and Full Year 2023
-
Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases
-
Carrols Restaurant Group, Inc. Reports Preliminary Sales Results for the Fourth Quarter and Full Year 2023
-
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
-
Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension
-
Collective Metals Announces Results of Phase II Soil Geochemical Sampling Program on its Princeton Project
-
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
-
Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
-
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization
-
R1 RCM Announces Preliminary Fourth Quarter Results
-
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
-
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
